SlideShare a Scribd company logo
1 of 14
Download to read offline
Scientific innovations
for more sustainable
growth
Copyright © 2022 Accenture. All rights reserved.
The Situation
The pace of innovation in life sciences
is at an all time high with unprecedented
scientific development in many areas. It’s just
the beginning of a significant and lasting shift.
With rising M&A costs, increasing pressures on
profitability, biotechs bringing products to
market themselves, and increasing pressures on
profitability, the entire landscape for biopharma
has shifted to an environment that requires
innovative and strategic approaches to
maintain pace.
But how can biopharma companies
sustain growth?
To better understand this challenge and determine pathways for success we conducted an extensive
analysis of over 300 M&A deals made by the top 30 biopharma companies between 2010 2021.
The key takeaway:
The traditional approach to fostering growth is no longer sustainable.
The Analysis
The good news is that there are clear pathways that biopharma companies can take
to remain competitive.
Rising Costs of Inorganic Growth:
1
Biotech transaction premiums reached record highs in 2021,
making inorganic growth increasingly expensive.
For M&A deals valued at more than $500M, the average takeout
premium in biopharma has grown from 51% in 2018 to roughly 71%
in 2021.1
In Q1 2022, public markets slowed with biotech performance dropping
and capital raised decreasing. Nevertheless, private markets remain
healthy with total VC investment in Q1 2022 being the second-largest
quarter of all time (after Q1 2021) for biotech-venture capital funding.2
How did we get here?
3 Factors eroding the sustainability of an inorganic growth strategy that relies heavily on M&A
1Accenture Research leveraging evaluate Pharma data. March 2022.
2Accenture Research leveraging evaluate Pharma data. April 2022.
Copyright © 2022 Accenture. All rights reserved. 4
4
Biotech going to market alone:
2
Smaller biotech companies are increasingly able to bring their products
to market themselves.
These players were responsible for approximately 55% of all drugs
brought to market between 2017 and 2021 a significant increase from
the preceding five year period (2012 2016) in which they accounted for
only 30%.3
Continued venture capital flow to biotechs noted above, further fuels
the escalating deal premiums.
How did we get here?
3 Factors eroding the sustainability of an inorganic growth strategy that relies heavily on M&A
3Accenture Research leveraging evaluate Pharma data. March 2022.
Copyright © 2022 Accenture. All rights reserved. 5
5
Increasing profitability pressures:
3
Margin declines in almost every therapeutic area is expected to be over
6% on average, with anti infectives expected to experience the largest
decline at 11.6%.4
A further decline in future revenues is also expected due to potential
U.S. policy reforms.
How did we get here?
3 Factors eroding the sustainability of an inorganic growth strategy that relies heavily on M&A
4New Science: A new economic reality for innovation and growth. Accenture 2021.
Copyright © 2022 Accenture. All rights reserved. 6
6
Assessing the options
Source: Accenture Research Growth Pathways Model 2021.
An analysis of all M&A transactions of top 30 biopharma companies by revenue,
leveraging S&P Cap IQ data. Percentages were calculated based on # of transactions.
Inorganic growth pathways: 2010-2021, number of transactions
36% 34% 16% 14%
Controller
geographic expansion
or vertical integration
Ecosystem
acquisitions of
know-how and
capabilities to
innovate faster
or reach customers
in new ways
Builder
bolt-on-late-stage
asset acquisitions
Architect
early-stage asset
acquisitions often with a
biotechnology platform
Through our analysis, we identified four growth pathways for biopharma companies. By
understanding these pathways, we can better anticipate trends toward innovation and success:
1. Architect:
Shift away from early-stage
assets towards platform-based
deals.
2. Builder:
Fewer asset-based Builder
pathways.
3. Ecosystem and Controller:
More Ecosystem and Controller
pathways thanks to nearly
unlimited funding from VC and
PE as well as increasing
opportunities ex-US.
Growth Pathways Predictions
Source: Accenture Research Growth Pathways Model 2021.
An analysis of all M&A transactions of top 30 biopharma companies by revenue, leveraging S&P Cap IQ data.
Percentages were calculated based on # of transactions.
Inorganic growth pathways: 2010-2021, number of transactions
36% 34% 16% 14%
Fewer late-stage
asset-based Builder
pathways.
35% 15% 25% 25%
Future (illustrative)
Architect
Early-stage asset
acquisitions often
with a biotechnology
platform
Builder
Bolt-on-late-
stage asset
acquisitions
Ecosystem
Acquisitions of
know-how and
capabilities to
innovate faster or
reach customers
in new ways
Controller
Geographic
expansion
or vertical
integration
Shift away from
early-stage assets
and towards
platform-based
deals.
More Ecosystem and Controller
pathways thanks to nearly unlimited
funding from VC and PE as well as
increasing opportunities ex-US.
Predictions
70% of all deals in the last 10 years were
Builder and Architect, but the traditional
Builder approach is becoming less appealing.
The Architect pathway grew by 30% in the
past five years and is expected to continue
to grow.
Ecosystem and Controller pathways account
for only 16% and 14% of M&A deals but we
anticipate that to increase.
Ecosystem will be utilized more often as
partnerships or M&A – to access capabilities
such as AI that accelerate time-to-market.
Controller will become more popular based
on increased opportunities in China
combined with pricing pressures in the US.
Growth Pathways Predictions
Source: Accenture Research Growth Pathways Model 2021.
An analysis of all M&A transactions of top 30 biopharma companies by revenue, leveraging S&P Cap IQ data.
Percentages were calculated based on # of transactions.
Inorganic growth pathways: 2010-2021, number of transactions
36% 34% 16% 14%
Fewer late-stage
asset-based Builder
pathways.
35% 15% 25% 25%
Future (illustrative)
Architect
Early-stage asset
acquisitions often
with a biotechnology
platform
Builder
Bolt-on-late-
stage asset
acquisitions
Ecosystem
Acquisitions of
know-how and
capabilities to
innovate faster or
reach customers
in new ways
Controller
Geographic
expansion
or vertical
integration
Shift away from
early-stage assets
and towards
platform-based
deals.
More Ecosystem and Controller
pathways thanks to nearly unlimited
funding from VC and PE as well as
increasing opportunities ex-US.
Predictions
Based on our analysis, we believe future successes will involve an increased focus
on platforms (Architect) and capabilities such as AI that support innovation at speed
(Ecosystem).
We identified three key actions companies should take in this new era
of innovation and growth:
1 Combine biotechnology platforms (bio-platforms)
and capabilities to create value.
2 Become a “cross-platform” organization and culture.
3 Create a novel science and technology (S&T) incubator
that reports to C-suite.
Copyright © 2022 Accenture. All rights reserved. 10
10
Combine biotechnology platforms (bio-platforms) and capabilities
to create value:
1
Different bio-platforms can and should help each other evolve in new directions
and create value together.
Ecosystem growth pathways that provide access to computational power, data,
and advanced analytics, as well as digital and automation technologies, help
power bio platforms to develop treatments faster.
Copyright © 2022 Accenture. All rights reserved. 11
11
Three key actions
3 Factors eroding the sustainability of an inorganic growth strategy that relies heavily on M&A
Become a “cross-platform” organization and culture:
2 Bio-platform approaches often include novel modalities which may require
different considerations for manufacturing, clinical trials, regulatory, etc.
Successful companies will learn to enter new modalities faster by evaluating
these considerations early on, such as being able to get clarity on new
manufacturing processes, to overcome the resistance in front of developing
new modalities.
They will learn to develop these assets faster and more efficiently and should be
applied to other bio-platforms and various therapeutic areas (TAs) to increase
speed. As bio-platforms and capabilities go across TAs, biopharma leaders will
need to adjust their operating model including their organization and culture
to realize the full value of their bio-platforms.
Copyright © 2022 Accenture. All rights reserved. 12
12
Three key actions
3 Factors eroding the sustainability of an inorganic growth strategy that relies heavily on M&A
Create a novel science and technology (S&T) incubator that reports
to C-suite:
3
If executed well, the bio-platform strategy will lead to a proliferation of assets
in various therapeutic areas (TAs).
It is not efficient to keep building new TA verticals and therefore biopharma will
need to externally source experts, skill sets, capabilities, and relationships
on demand.
Copyright © 2022 Accenture. All rights reserved. 13
13
Three key actions
3 Factors eroding the sustainability of an inorganic growth strategy that relies heavily on M&A
To read the full report go to accenture.com/sustain-growth
Acknowledgements:
The authors would like to thank Nic Simitzi for his support in forming the overall perspective and performing the analyses in this report;
and Vincenzo Palermo and data science team for the growth pathways AI-algorithm, stock price and biopharma company clustering analyses.
Reach out to the authors to learn more:
Austin Corbett
Managing Director,
Life Sciences Strategy
austin.j.corbett@accenture.com
Kenneth R. Munie
Managing Director,
Life Sciences Strategy Lead
kenneth.r.munie@accenture.com
Stuart Henderson
Senior Managing Director,
Northeast Market Unit Lead
stuart.t.henderson@accenture.com
Selen Karaca-Griffin
Senior Principal,
Global Life Sciences Research Lead
selen.karca-griffin@accenture.com
Dr. Petra Jantzer
Senior Managing Director,
Global Life Sciences Lead
petra.jantzer@accenture.com
Copyright © 2022 Accenture. All rights reserved.

More Related Content

What's hot

What's hot (20)

A passwordless enterprise journey
A passwordless enterprise journeyA passwordless enterprise journey
A passwordless enterprise journey
 
Digitizing Business Services
Digitizing Business ServicesDigitizing Business Services
Digitizing Business Services
 
Nonprofit reinvention in a time of unprecedented change
 Nonprofit reinvention in a time of unprecedented change Nonprofit reinvention in a time of unprecedented change
Nonprofit reinvention in a time of unprecedented change
 
Accenture Tech Vision 2020 - Overview
Accenture Tech Vision 2020 - OverviewAccenture Tech Vision 2020 - Overview
Accenture Tech Vision 2020 - Overview
 
Accenture Tech Vision 2020 - Trend 2
Accenture Tech Vision 2020 - Trend 2Accenture Tech Vision 2020 - Trend 2
Accenture Tech Vision 2020 - Trend 2
 
More deals, less money: the Black founder funding journey
More deals, less money: the Black founder funding journeyMore deals, less money: the Black founder funding journey
More deals, less money: the Black founder funding journey
 
Pathways to Profitability for the Communications Industry
Pathways to Profitability for the Communications IndustryPathways to Profitability for the Communications Industry
Pathways to Profitability for the Communications Industry
 
Health Experience: The difference between loyalty & leaving
Health Experience: The difference between loyalty & leavingHealth Experience: The difference between loyalty & leaving
Health Experience: The difference between loyalty & leaving
 
Transforming the Industry That Transformed the World
Transforming the Industry That Transformed the WorldTransforming the Industry That Transformed the World
Transforming the Industry That Transformed the World
 
The Rise of Forerunners | Accenture
The Rise of Forerunners | AccentureThe Rise of Forerunners | Accenture
The Rise of Forerunners | Accenture
 
INTIENT Patient
INTIENT Patient INTIENT Patient
INTIENT Patient
 
New Value in Sustainability
New Value in SustainabilityNew Value in Sustainability
New Value in Sustainability
 
INTIENT Patient Solution
INTIENT Patient SolutionINTIENT Patient Solution
INTIENT Patient Solution
 
Get the most from your cloud journey
Get the most from your cloud journeyGet the most from your cloud journey
Get the most from your cloud journey
 
The Changing Joule Dynamic | Accenture
The Changing Joule Dynamic | AccentureThe Changing Joule Dynamic | Accenture
The Changing Joule Dynamic | Accenture
 
The Industrialist: Trends & Innovations - July 2023
The Industrialist: Trends & Innovations - July 2023The Industrialist: Trends & Innovations - July 2023
The Industrialist: Trends & Innovations - July 2023
 
Digitaizing Business Services
Digitaizing Business ServicesDigitaizing Business Services
Digitaizing Business Services
 
Reinventing the client journey
Reinventing the client journeyReinventing the client journey
Reinventing the client journey
 
It's learning. Just not as we know it.
It's learning. Just not as we know it.It's learning. Just not as we know it.
It's learning. Just not as we know it.
 
New ways to apply infrastructure data for better business outcomes
New ways to apply infrastructure data for better business outcomesNew ways to apply infrastructure data for better business outcomes
New ways to apply infrastructure data for better business outcomes
 

Similar to Biopharma's search for sustainable growth

Ey beyondborders: unlocking value
Ey beyondborders: unlocking valueEy beyondborders: unlocking value
Ey beyondborders: unlocking value
Frédéric Barillet
 
Chemical_innovation_An_investment_for_the_ages
Chemical_innovation_An_investment_for_the_agesChemical_innovation_An_investment_for_the_ages
Chemical_innovation_An_investment_for_the_ages
Tim Biggs
 
Catalent (CTLT) Equity Report
Catalent (CTLT) Equity ReportCatalent (CTLT) Equity Report
Catalent (CTLT) Equity Report
Leon Stempert
 
Clx investor presentation
Clx investor presentationClx investor presentation
Clx investor presentation
cloroxir2016
 
Medical_Devices_Industry
Medical_Devices_IndustryMedical_Devices_Industry
Medical_Devices_Industry
Virendra K
 

Similar to Biopharma's search for sustainable growth (20)

Syngene Ipo Note - Subscribe for long term gains
Syngene Ipo Note - Subscribe for long term gainsSyngene Ipo Note - Subscribe for long term gains
Syngene Ipo Note - Subscribe for long term gains
 
Stepping Up the Pace
Stepping Up the PaceStepping Up the Pace
Stepping Up the Pace
 
Genetic Technologies Investor Presentation March 2021
Genetic Technologies Investor Presentation March 2021Genetic Technologies Investor Presentation March 2021
Genetic Technologies Investor Presentation March 2021
 
Ey beyondborders: unlocking value
Ey beyondborders: unlocking valueEy beyondborders: unlocking value
Ey beyondborders: unlocking value
 
Matthueu Lamiaux-Enfermedades transmitidas por vectores
Matthueu Lamiaux-Enfermedades transmitidas por vectoresMatthueu Lamiaux-Enfermedades transmitidas por vectores
Matthueu Lamiaux-Enfermedades transmitidas por vectores
 
DuPont Presents at Jefferies 10th Annual Global Industrials Conference
DuPont Presents at Jefferies 10th Annual Global Industrials ConferenceDuPont Presents at Jefferies 10th Annual Global Industrials Conference
DuPont Presents at Jefferies 10th Annual Global Industrials Conference
 
Chemical_innovation_An_investment_for_the_ages
Chemical_innovation_An_investment_for_the_agesChemical_innovation_An_investment_for_the_ages
Chemical_innovation_An_investment_for_the_ages
 
Opportunity analysis of life science tools market in India - A srinivas sash...
Opportunity analysis of life science tools market in India - A  srinivas sash...Opportunity analysis of life science tools market in India - A  srinivas sash...
Opportunity analysis of life science tools market in India - A srinivas sash...
 
Top 5 strategy of b2b supply chains trends and opportunities
Top 5 strategy of b2b supply chains trends and opportunitiesTop 5 strategy of b2b supply chains trends and opportunities
Top 5 strategy of b2b supply chains trends and opportunities
 
Catalent (CTLT) Equity Report
Catalent (CTLT) Equity ReportCatalent (CTLT) Equity Report
Catalent (CTLT) Equity Report
 
Investor deck (fy16 q4) final 9.7.16
Investor deck (fy16 q4) final 9.7.16Investor deck (fy16 q4) final 9.7.16
Investor deck (fy16 q4) final 9.7.16
 
Emerging Markets Digital Health Outlook 2023.pdf
Emerging Markets Digital Health Outlook 2023.pdfEmerging Markets Digital Health Outlook 2023.pdf
Emerging Markets Digital Health Outlook 2023.pdf
 
Investor Overview
Investor OverviewInvestor Overview
Investor Overview
 
Manufacturing Industry Survey Report
Manufacturing Industry Survey ReportManufacturing Industry Survey Report
Manufacturing Industry Survey Report
 
Augmedix Equity Research Report - Brendan Hegarty.pdf
Augmedix Equity Research Report - Brendan Hegarty.pdfAugmedix Equity Research Report - Brendan Hegarty.pdf
Augmedix Equity Research Report - Brendan Hegarty.pdf
 
Whitepaper: Patent strategies in the 2012 economic environment
Whitepaper: Patent strategies in the 2012 economic environmentWhitepaper: Patent strategies in the 2012 economic environment
Whitepaper: Patent strategies in the 2012 economic environment
 
Clx investor presentation
Clx investor presentationClx investor presentation
Clx investor presentation
 
Unlocking Trapped Value of Innovation Investments​
Unlocking Trapped Value of Innovation Investments​Unlocking Trapped Value of Innovation Investments​
Unlocking Trapped Value of Innovation Investments​
 
Medical_Devices_Industry
Medical_Devices_IndustryMedical_Devices_Industry
Medical_Devices_Industry
 
DuPont at J.P. Morgan Aviation, Transportation and Industrials Conference
DuPont at J.P. Morgan Aviation, Transportation and Industrials ConferenceDuPont at J.P. Morgan Aviation, Transportation and Industrials Conference
DuPont at J.P. Morgan Aviation, Transportation and Industrials Conference
 

More from accenture

More from accenture (20)

The Industrialist: Trends & Innovations - January 2024
The Industrialist: Trends & Innovations - January 2024The Industrialist: Trends & Innovations - January 2024
The Industrialist: Trends & Innovations - January 2024
 
The Industrialist: Trends & Innovations - September 2023
The Industrialist: Trends & Innovations - September 2023The Industrialist: Trends & Innovations - September 2023
The Industrialist: Trends & Innovations - September 2023
 
Accenture Technology Vision - How the trends apply to higher education
Accenture Technology Vision - How the trends apply to higher education Accenture Technology Vision - How the trends apply to higher education
Accenture Technology Vision - How the trends apply to higher education
 
Accenture Technology Vision - How the trends apply to higher education
Accenture Technology Vision - How the trends apply to higher education Accenture Technology Vision - How the trends apply to higher education
Accenture Technology Vision - How the trends apply to higher education
 
Engineering Services: con gli ingegneri per creare valore sostenibile
Engineering Services: con gli ingegneri per creare valore sostenibileEngineering Services: con gli ingegneri per creare valore sostenibile
Engineering Services: con gli ingegneri per creare valore sostenibile
 
Digital Euro: Implications for the Financial System
Digital Euro: Implications for the Financial SystemDigital Euro: Implications for the Financial System
Digital Euro: Implications for the Financial System
 
The Industrialist: Trends & Innovations - June 2023
The Industrialist: Trends & Innovations - June 2023The Industrialist: Trends & Innovations - June 2023
The Industrialist: Trends & Innovations - June 2023
 
Semiconductor Gender Parity Study
Semiconductor Gender Parity StudySemiconductor Gender Parity Study
Semiconductor Gender Parity Study
 
The Industrialist: Trends & Innovations - March 2023
The Industrialist: Trends & Innovations - March 2023The Industrialist: Trends & Innovations - March 2023
The Industrialist: Trends & Innovations - March 2023
 
Free to be 100% me
Free to be 100% meFree to be 100% me
Free to be 100% me
 
The Industrialist: Trends & Innovations - February 2023
The Industrialist: Trends & Innovations - February 2023The Industrialist: Trends & Innovations - February 2023
The Industrialist: Trends & Innovations - February 2023
 
Mundo gamer e a oportunidade de entrada pela abordagem do movimento
Mundo gamer e a oportunidade de entrada pela abordagem do movimentoMundo gamer e a oportunidade de entrada pela abordagem do movimento
Mundo gamer e a oportunidade de entrada pela abordagem do movimento
 
The Industrialist: Trends & Innovations - January 2023
The Industrialist: Trends & Innovations - January 2023The Industrialist: Trends & Innovations - January 2023
The Industrialist: Trends & Innovations - January 2023
 
Reimagining the Agenda | Accenture
Reimagining the Agenda | AccentureReimagining the Agenda | Accenture
Reimagining the Agenda | Accenture
 
Climate Leadership Eleventh Hour | Accenture
Climate Leadership Eleventh Hour | AccentureClimate Leadership Eleventh Hour | Accenture
Climate Leadership Eleventh Hour | Accenture
 
Sustainable Value Chain
Sustainable Value ChainSustainable Value Chain
Sustainable Value Chain
 
Chemical Companies in the Metaverse
Chemical Companies in the MetaverseChemical Companies in the Metaverse
Chemical Companies in the Metaverse
 
Sustainable Value Chain
Sustainable Value ChainSustainable Value Chain
Sustainable Value Chain
 
The Industrialist: Trends & Innovations - November 2022
The Industrialist: Trends & Innovations - November 2022The Industrialist: Trends & Innovations - November 2022
The Industrialist: Trends & Innovations - November 2022
 
Metaverse opportunities for the communications industry
 Metaverse opportunities for the communications industry Metaverse opportunities for the communications industry
Metaverse opportunities for the communications industry
 

Recently uploaded

Recently uploaded (20)

The Value of Certifying Products for FDO _ Paul at FIDO Alliance.pdf
The Value of Certifying Products for FDO _ Paul at FIDO Alliance.pdfThe Value of Certifying Products for FDO _ Paul at FIDO Alliance.pdf
The Value of Certifying Products for FDO _ Paul at FIDO Alliance.pdf
 
How we scaled to 80K users by doing nothing!.pdf
How we scaled to 80K users by doing nothing!.pdfHow we scaled to 80K users by doing nothing!.pdf
How we scaled to 80K users by doing nothing!.pdf
 
Portal Kombat : extension du réseau de propagande russe
Portal Kombat : extension du réseau de propagande russePortal Kombat : extension du réseau de propagande russe
Portal Kombat : extension du réseau de propagande russe
 
Google I/O Extended 2024 Warsaw
Google I/O Extended 2024 WarsawGoogle I/O Extended 2024 Warsaw
Google I/O Extended 2024 Warsaw
 
Using IESVE for Room Loads Analysis - UK & Ireland
Using IESVE for Room Loads Analysis - UK & IrelandUsing IESVE for Room Loads Analysis - UK & Ireland
Using IESVE for Room Loads Analysis - UK & Ireland
 
Simplified FDO Manufacturing Flow with TPMs _ Liam at Infineon.pdf
Simplified FDO Manufacturing Flow with TPMs _ Liam at Infineon.pdfSimplified FDO Manufacturing Flow with TPMs _ Liam at Infineon.pdf
Simplified FDO Manufacturing Flow with TPMs _ Liam at Infineon.pdf
 
Human Expert Website Manual WCAG 2.0 2.1 2.2 Audit - Digital Accessibility Au...
Human Expert Website Manual WCAG 2.0 2.1 2.2 Audit - Digital Accessibility Au...Human Expert Website Manual WCAG 2.0 2.1 2.2 Audit - Digital Accessibility Au...
Human Expert Website Manual WCAG 2.0 2.1 2.2 Audit - Digital Accessibility Au...
 
Event-Driven Architecture Masterclass: Engineering a Robust, High-performance...
Event-Driven Architecture Masterclass: Engineering a Robust, High-performance...Event-Driven Architecture Masterclass: Engineering a Robust, High-performance...
Event-Driven Architecture Masterclass: Engineering a Robust, High-performance...
 
Long journey of Ruby Standard library at RubyKaigi 2024
Long journey of Ruby Standard library at RubyKaigi 2024Long journey of Ruby Standard library at RubyKaigi 2024
Long journey of Ruby Standard library at RubyKaigi 2024
 
Microsoft CSP Briefing Pre-Engagement - Questionnaire
Microsoft CSP Briefing Pre-Engagement - QuestionnaireMicrosoft CSP Briefing Pre-Engagement - Questionnaire
Microsoft CSP Briefing Pre-Engagement - Questionnaire
 
Linux Foundation Edge _ Overview of FDO Software Components _ Randy at Intel.pdf
Linux Foundation Edge _ Overview of FDO Software Components _ Randy at Intel.pdfLinux Foundation Edge _ Overview of FDO Software Components _ Randy at Intel.pdf
Linux Foundation Edge _ Overview of FDO Software Components _ Randy at Intel.pdf
 
Working together SRE & Platform Engineering
Working together SRE & Platform EngineeringWorking together SRE & Platform Engineering
Working together SRE & Platform Engineering
 
WebRTC and SIP not just audio and video @ OpenSIPS 2024
WebRTC and SIP not just audio and video @ OpenSIPS 2024WebRTC and SIP not just audio and video @ OpenSIPS 2024
WebRTC and SIP not just audio and video @ OpenSIPS 2024
 
Event-Driven Architecture Masterclass: Integrating Distributed Data Stores Ac...
Event-Driven Architecture Masterclass: Integrating Distributed Data Stores Ac...Event-Driven Architecture Masterclass: Integrating Distributed Data Stores Ac...
Event-Driven Architecture Masterclass: Integrating Distributed Data Stores Ac...
 
Overview of Hyperledger Foundation
Overview of Hyperledger FoundationOverview of Hyperledger Foundation
Overview of Hyperledger Foundation
 
1111 ChatGPT Prompts PDF Free Download - Prompts for ChatGPT
1111 ChatGPT Prompts PDF Free Download - Prompts for ChatGPT1111 ChatGPT Prompts PDF Free Download - Prompts for ChatGPT
1111 ChatGPT Prompts PDF Free Download - Prompts for ChatGPT
 
Continuing Bonds Through AI: A Hermeneutic Reflection on Thanabots
Continuing Bonds Through AI: A Hermeneutic Reflection on ThanabotsContinuing Bonds Through AI: A Hermeneutic Reflection on Thanabots
Continuing Bonds Through AI: A Hermeneutic Reflection on Thanabots
 
WebAssembly is Key to Better LLM Performance
WebAssembly is Key to Better LLM PerformanceWebAssembly is Key to Better LLM Performance
WebAssembly is Key to Better LLM Performance
 
Your enemies use GenAI too - staying ahead of fraud with Neo4j
Your enemies use GenAI too - staying ahead of fraud with Neo4jYour enemies use GenAI too - staying ahead of fraud with Neo4j
Your enemies use GenAI too - staying ahead of fraud with Neo4j
 
State of the Smart Building Startup Landscape 2024!
State of the Smart Building Startup Landscape 2024!State of the Smart Building Startup Landscape 2024!
State of the Smart Building Startup Landscape 2024!
 

Biopharma's search for sustainable growth

  • 1. Scientific innovations for more sustainable growth Copyright © 2022 Accenture. All rights reserved.
  • 2. The Situation The pace of innovation in life sciences is at an all time high with unprecedented scientific development in many areas. It’s just the beginning of a significant and lasting shift. With rising M&A costs, increasing pressures on profitability, biotechs bringing products to market themselves, and increasing pressures on profitability, the entire landscape for biopharma has shifted to an environment that requires innovative and strategic approaches to maintain pace. But how can biopharma companies sustain growth?
  • 3. To better understand this challenge and determine pathways for success we conducted an extensive analysis of over 300 M&A deals made by the top 30 biopharma companies between 2010 2021. The key takeaway: The traditional approach to fostering growth is no longer sustainable. The Analysis The good news is that there are clear pathways that biopharma companies can take to remain competitive.
  • 4. Rising Costs of Inorganic Growth: 1 Biotech transaction premiums reached record highs in 2021, making inorganic growth increasingly expensive. For M&A deals valued at more than $500M, the average takeout premium in biopharma has grown from 51% in 2018 to roughly 71% in 2021.1 In Q1 2022, public markets slowed with biotech performance dropping and capital raised decreasing. Nevertheless, private markets remain healthy with total VC investment in Q1 2022 being the second-largest quarter of all time (after Q1 2021) for biotech-venture capital funding.2 How did we get here? 3 Factors eroding the sustainability of an inorganic growth strategy that relies heavily on M&A 1Accenture Research leveraging evaluate Pharma data. March 2022. 2Accenture Research leveraging evaluate Pharma data. April 2022. Copyright © 2022 Accenture. All rights reserved. 4 4
  • 5. Biotech going to market alone: 2 Smaller biotech companies are increasingly able to bring their products to market themselves. These players were responsible for approximately 55% of all drugs brought to market between 2017 and 2021 a significant increase from the preceding five year period (2012 2016) in which they accounted for only 30%.3 Continued venture capital flow to biotechs noted above, further fuels the escalating deal premiums. How did we get here? 3 Factors eroding the sustainability of an inorganic growth strategy that relies heavily on M&A 3Accenture Research leveraging evaluate Pharma data. March 2022. Copyright © 2022 Accenture. All rights reserved. 5 5
  • 6. Increasing profitability pressures: 3 Margin declines in almost every therapeutic area is expected to be over 6% on average, with anti infectives expected to experience the largest decline at 11.6%.4 A further decline in future revenues is also expected due to potential U.S. policy reforms. How did we get here? 3 Factors eroding the sustainability of an inorganic growth strategy that relies heavily on M&A 4New Science: A new economic reality for innovation and growth. Accenture 2021. Copyright © 2022 Accenture. All rights reserved. 6 6
  • 7. Assessing the options Source: Accenture Research Growth Pathways Model 2021. An analysis of all M&A transactions of top 30 biopharma companies by revenue, leveraging S&P Cap IQ data. Percentages were calculated based on # of transactions. Inorganic growth pathways: 2010-2021, number of transactions 36% 34% 16% 14% Controller geographic expansion or vertical integration Ecosystem acquisitions of know-how and capabilities to innovate faster or reach customers in new ways Builder bolt-on-late-stage asset acquisitions Architect early-stage asset acquisitions often with a biotechnology platform Through our analysis, we identified four growth pathways for biopharma companies. By understanding these pathways, we can better anticipate trends toward innovation and success:
  • 8. 1. Architect: Shift away from early-stage assets towards platform-based deals. 2. Builder: Fewer asset-based Builder pathways. 3. Ecosystem and Controller: More Ecosystem and Controller pathways thanks to nearly unlimited funding from VC and PE as well as increasing opportunities ex-US. Growth Pathways Predictions Source: Accenture Research Growth Pathways Model 2021. An analysis of all M&A transactions of top 30 biopharma companies by revenue, leveraging S&P Cap IQ data. Percentages were calculated based on # of transactions. Inorganic growth pathways: 2010-2021, number of transactions 36% 34% 16% 14% Fewer late-stage asset-based Builder pathways. 35% 15% 25% 25% Future (illustrative) Architect Early-stage asset acquisitions often with a biotechnology platform Builder Bolt-on-late- stage asset acquisitions Ecosystem Acquisitions of know-how and capabilities to innovate faster or reach customers in new ways Controller Geographic expansion or vertical integration Shift away from early-stage assets and towards platform-based deals. More Ecosystem and Controller pathways thanks to nearly unlimited funding from VC and PE as well as increasing opportunities ex-US. Predictions
  • 9. 70% of all deals in the last 10 years were Builder and Architect, but the traditional Builder approach is becoming less appealing. The Architect pathway grew by 30% in the past five years and is expected to continue to grow. Ecosystem and Controller pathways account for only 16% and 14% of M&A deals but we anticipate that to increase. Ecosystem will be utilized more often as partnerships or M&A – to access capabilities such as AI that accelerate time-to-market. Controller will become more popular based on increased opportunities in China combined with pricing pressures in the US. Growth Pathways Predictions Source: Accenture Research Growth Pathways Model 2021. An analysis of all M&A transactions of top 30 biopharma companies by revenue, leveraging S&P Cap IQ data. Percentages were calculated based on # of transactions. Inorganic growth pathways: 2010-2021, number of transactions 36% 34% 16% 14% Fewer late-stage asset-based Builder pathways. 35% 15% 25% 25% Future (illustrative) Architect Early-stage asset acquisitions often with a biotechnology platform Builder Bolt-on-late- stage asset acquisitions Ecosystem Acquisitions of know-how and capabilities to innovate faster or reach customers in new ways Controller Geographic expansion or vertical integration Shift away from early-stage assets and towards platform-based deals. More Ecosystem and Controller pathways thanks to nearly unlimited funding from VC and PE as well as increasing opportunities ex-US. Predictions
  • 10. Based on our analysis, we believe future successes will involve an increased focus on platforms (Architect) and capabilities such as AI that support innovation at speed (Ecosystem). We identified three key actions companies should take in this new era of innovation and growth: 1 Combine biotechnology platforms (bio-platforms) and capabilities to create value. 2 Become a “cross-platform” organization and culture. 3 Create a novel science and technology (S&T) incubator that reports to C-suite. Copyright © 2022 Accenture. All rights reserved. 10 10
  • 11. Combine biotechnology platforms (bio-platforms) and capabilities to create value: 1 Different bio-platforms can and should help each other evolve in new directions and create value together. Ecosystem growth pathways that provide access to computational power, data, and advanced analytics, as well as digital and automation technologies, help power bio platforms to develop treatments faster. Copyright © 2022 Accenture. All rights reserved. 11 11 Three key actions 3 Factors eroding the sustainability of an inorganic growth strategy that relies heavily on M&A
  • 12. Become a “cross-platform” organization and culture: 2 Bio-platform approaches often include novel modalities which may require different considerations for manufacturing, clinical trials, regulatory, etc. Successful companies will learn to enter new modalities faster by evaluating these considerations early on, such as being able to get clarity on new manufacturing processes, to overcome the resistance in front of developing new modalities. They will learn to develop these assets faster and more efficiently and should be applied to other bio-platforms and various therapeutic areas (TAs) to increase speed. As bio-platforms and capabilities go across TAs, biopharma leaders will need to adjust their operating model including their organization and culture to realize the full value of their bio-platforms. Copyright © 2022 Accenture. All rights reserved. 12 12 Three key actions 3 Factors eroding the sustainability of an inorganic growth strategy that relies heavily on M&A
  • 13. Create a novel science and technology (S&T) incubator that reports to C-suite: 3 If executed well, the bio-platform strategy will lead to a proliferation of assets in various therapeutic areas (TAs). It is not efficient to keep building new TA verticals and therefore biopharma will need to externally source experts, skill sets, capabilities, and relationships on demand. Copyright © 2022 Accenture. All rights reserved. 13 13 Three key actions 3 Factors eroding the sustainability of an inorganic growth strategy that relies heavily on M&A
  • 14. To read the full report go to accenture.com/sustain-growth Acknowledgements: The authors would like to thank Nic Simitzi for his support in forming the overall perspective and performing the analyses in this report; and Vincenzo Palermo and data science team for the growth pathways AI-algorithm, stock price and biopharma company clustering analyses. Reach out to the authors to learn more: Austin Corbett Managing Director, Life Sciences Strategy austin.j.corbett@accenture.com Kenneth R. Munie Managing Director, Life Sciences Strategy Lead kenneth.r.munie@accenture.com Stuart Henderson Senior Managing Director, Northeast Market Unit Lead stuart.t.henderson@accenture.com Selen Karaca-Griffin Senior Principal, Global Life Sciences Research Lead selen.karca-griffin@accenture.com Dr. Petra Jantzer Senior Managing Director, Global Life Sciences Lead petra.jantzer@accenture.com Copyright © 2022 Accenture. All rights reserved.